ArticleFrontiers in genetics2025
Construction of a novel prognostic model for gastric cancer based on pharmacokinetics-related genes and comprehensive prognostic analysis.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Absorption, distribution, metabolism, and excretion of drugs-related genes (ADMERGs), pivotal in cancer occurrence, development, and chemotherapy resistance, lack investigation in gastric cancer (GC). Thus, this study aims to build a prognostic model for gastric cancer utilizing ADMERGs. Methods: The GC-related datasets, including TCGA-GC, GSE62254, GSE163558 and GSE13911, as well as 298 ADMERGs, were retrieved in this study. Prognostic risk models associated with ADME were developed utilizing univariate Cox analysis, followed by additional refinement using the least absolute shrinkage and selection operator (LASSO). The entire pool of gastric cancer (GC) patient samples was partitioned into high and low-risk categories, delineated by the median value of their respective risk scores. Within these two distinct groups, we conducted enrichment analysis, immune infiltration, and prognostic evaluation of ADME-related prognostic genes to uncover their molecular mechanisms in GC. The construction of ceRNA regulatory networks was undertaken to analyse the prognostic gene regulatory mechanisms. We analyzed single-cell data in GC to investigate the mechanisms driving its onset and progression at the cellular level. Additionally, we validated the expression trends of prognostic genes in clinical samples using RT-qPCR. Results: A prognostic model for GC was established and validated, comprising five genes ( Conclusion: We have developed and validated an innovative prognostic risk model for GC, revealing that elevated ADMERGs risk scores are indicative of unfavorable prognosis and diminished immunotherapy response. These findings furnish molecular evidence regarding the participation of ADMERGs in modulating the immune microenvironment and therapeutic responsiveness in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.